Navigation Links
Presentations of Cempra Pharmaceutical's CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
Date:10/28/2009

ighly correlated susceptibility results across multiple S. aureus strains.

An oral presentation, scheduled at 3:30 p.m. EDT, October 31, presents evidence, through a pharmacokinetic-pharmacodynamic model based on drug clearance data from 69 healthy subjects, that a loading dose of CEM-102 on the first day of treatment can generate significantly better antibacterial effects compared to regimens without a loading dose. The analysis showed that a loading dose of at least 1,200 mg twice-daily on the first treatment day followed by 600 mg twice-daily on subsequent days optimized the antibacterial effect of CEM-102. This provides the rationale for the unique loading dose regimen employed in the ongoing Phase 2/3 clinical trial to minimize bacterial resistance and optimize efficacy.

"Antibiotic-resistant S. aureus strains are an increasing therapeutic problem both in the community as well as in the hospital setting," said Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra Pharmaceuticals. "New treatment alternatives are in great need, particularly agents that are safe, administered orally, and can prevent patients from being admitted to the hospital. The potent anti-staph activity of CEM-102, its long safety record and low incidence of resistance make it a highly promising anti-MRSA drug candidate."

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing i
'/>"/>

SOURCE Cempra Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
2. Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)
3. IDM Pharma Announces Upcoming Clinical Data Presentations
4. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
5. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
8. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
9. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
10. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
11. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014  Encision Inc. (OTCQB:ECIA), a medical device company ... burns in minimally invasive surgery, today announced financial results ... 2014. The Company posted quarterly net revenue ... $414 thousand, or $(0.04) per share. These results compare ... loss of $50 thousand, or $(0.01) per share, in ...
(Date:10/31/2014)... , Oct. 31, 2014 /CNW Telbec/ - Ergoresearch ... its strategic plan, for accelerated growth in terms of ... and revenues reached $17,862,341. Net income amounted to $1,230,153. ... for the first time in the Company,s history. ... Company joined the forces of its subsidiaries, merging in ...
(Date:10/31/2014)... Research and ... the  "Process Validation in the US and EU ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key topics to include:  ... to Process Validation for Pharmaceutical and Biopharmaceutical Products ... Process Validation Guidance EU Process Validation ...
Breaking Medicine Technology:Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4
... mass index (BMI) should be taken into account when assessing ... Cancer Treatment Centers of America (CTCA), ... of vitamin D compared to non-obese patients. , , ... , The association between vitamin D and obesity remains unsettled ...
... Calif., June 12 Masimo (Nasdaq: MASI ... and Low-Perfusion pulse oximetry, announced today that three new ... Masimo PVI as a noninvasive and continuous measure of ... at the European Society of Anaesthesiology (ESA) Annual Congress ...
Cached Medicine Technology:Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Sleep apnea may make it ... you parked your car or left your house keys, a ... sleep apnea showed that this ability -- called spatial memory ... (REM) sleep, even when other stages of sleep weren,t affected. ... dreams typically occur. "We,ve shown for the first time ...
(Date:10/31/2014)... lab device to give cancer researchers an unprecedented microscopic ... spread through the body, causing more than 90 percent ... tumor cells travel, the device could uncover new ways ... the university,s Whiting School of Engineering and its Institute ... new system recently in the journal Cancer Research ...
(Date:10/31/2014)... combination that can trigger the self-destruct process in lung ... according to research that will be presented at the ... next week*. , When healthy cells are no longer ... self destruction. But cancer cells swerve away from this ... grow out of control – causing tumours to form. ...
(Date:10/31/2014)... Phoenix, AZ (PRWEB) October 31, 2014 ... off all dental treatments for November. Whether patients simply need ... there is no better time than now to get that ... but many patients put off routine and even essential treatments ... patients can enjoy substantial savings on any treatments offered by ...
(Date:10/31/2014)... 31, 2014 Adults 65 and ... their Medicare coverage during the current open enrollment ... library for step-by-step guidance, the company announced today. ... on choosing the correct Medicare Advantage plan, understanding ... open enrollment. , “With just one month remaining ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2
... COLUMBUS, Ohio -- An Ohio State University mathematician and his ... cells and abnormal cells, such as cancer cells, based on ... creating mathematical equations that describe the shape and motion of ... is in its early stages, it represents an entirely new ...
... TUESDAY, Jan. 25 (HealthDay News) -- Elderly patients with ... emergency department often do not comprehend why they are ... or nurses, a new study finds. U.S. researchers ... an emergency department and found that those with cognitive ...
... joined state, community and university partners on Jan. 25 ... health. The grant project will serve more than 1,200 ... cognitive and behavioral development services. Project LAUNCH ... serve children ages birth to 8 years old and ...
... , TUESDAY, Jan. 25 (HealthDay News) -- Epilepsy was the ... Frederic Chopin, according to a new study. Researchers reached ... the musician,s own descriptions of his hallucinations -- including his ... accounts of his life written by pupils and friends such ...
... , TUESDAY, Jan. 25 (HealthDay News) -- Following a series ... Administration is asking an expert panel to vote Tuesday on ... Over the past five years, there have been 68 recalls ... in cardiac arrest in hopes of getting the heart to ...
... ultrasound investigation and a blood test to measure the level ... future heart failure following acute coronary syndromes. This is the ... Sweden. Acute coronary syndromes, such as myocardial infarction and ... medical care and death in Sweden for both women and ...
Cached Medicine News:Health News:Researchers use cell 'profiling' to detect abnormalities -- including cancer 2Health News:Researchers use cell 'profiling' to detect abnormalities -- including cancer 3Health News:Elderly With Dementia, Delirium Confused by ER Visits: Study 2Health News:Federal grant helps LAUNCH improvements in children's health 2Health News:FDA Looking for Tougher Standards for External Defibrillators 2Health News:Ultrasound and a blood test can increase survival after myocardial infarction 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: